Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 4/20 | 0.57 |
| ▸ | NPC1 | O15118 | 3/20 | 0.57 |
| ▸ | HPGD | P15428 | 2/20 | 0.57 |
| ▸ | CRHBP | P24387 | 1/20 | 0.57 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.51 |
| ▸ | LMNA | P02545 | 2/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.51 |
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | RECQL | P46063 | 1/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.50 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7565510 | 0.86 | RAB9A (0.71) | RAB9ANPC1HPGDCRHBPCRHR2 | |
| SCHEMBL2535856 | 0.86 | SMN1; SMN2 (0.62) | RAB9ANPC1HPGDSMN1; SMN2KDM4E | |
| Ethyl Phenylcarbamate SCHEMBL10645999 | 0.83 | RAB9A (0.73) | RAB9ANPC1HPGDCRHBPCRHR2 | |
| SCHEMBL122021 | 0.83 | RAB9A (0.64) | RAB9ANPC1HPGDSMN1; SMN2KDM4E | |
| SCHEMBL3769103 | 0.82 | MAPT (0.66) | RAB9ANPC1HPGDSMN1; SMN2KDM4E | |
| SCHEMBL7565512 | 0.81 | RAB9A (0.70) | RAB9ANPC1HPGDCRHBPCRHR2 | |
| Ethyl Phenylcarbamate SCHEMBL264865 | 0.81 | RAB9A (0.75) | RAB9ANPC1HPGDCRHBPCRHR2 | |
| Ethyl Phenylcarbamate SCHEMBL11593824 | 0.81 | RAB9A (0.75) | RAB9ANPC1HPGDCRHBPCRHR2 | |
| SCHEMBL9146676 | 0.81 | LMNA (0.68) | RAB9ANPC1HPGDCRHBPCRHR2 | |
| SCHEMBL11790359 | 0.81 | RAB9A (0.65) | RAB9ANPC1HPGDCRHBPCRHR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 97 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3242875-B1 | 4,5-DIHYDROIMIDAZOLE DERIVATIVES AND THEIR USE AS HISTONE DEMETHYLASE (KDM2B) INHIBITORS | GENENTECH INC (US) | 2022-02-23 | — | — | EP | claimed |
| US-10202354-B2 | Therapeutic compounds and uses thereof | GENENTECH, INC. (US) | 2019-02-12 | — | — | US | claimed |
| US-20180022707-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2018-01-25 | — | — | US | claimed |
| EP-3242875-A1 | 4,5-DIHYDROIMIDAZOLE DERIVATIVES AND THEIR USE AS HISTONE DEMETHYLASE (KDM2B) INHIBITORS | Genentech, Inc. (US) | 2017-11-15 | — | — | EP | claimed |
| WO-2016112251-A1 | 4,5-DIHYDROIMIDAZOLE DERIVATIVES AND THEIR USE AS HISTONE DEMETHYLASE (KDM2B) INHIBITORS | GENENTECH, INC. (US) | 2016-07-14 | — | — | WO | claimed |
| EP-1087946-B1 | ARYL ALKANOYLPYRIDAZINES | MERCK PATENT GMBH (DE) | 2007-01-10 | — | — | EP | claimed |
| US-7041747-B1 | Polymerizable compositions in non-flowable forms | HENKEL CORPORATION (US) | 2006-05-09 | — | — | US | claimed |
| WO-2003018019-A2 | NEW USE OF CYCLIC COMPOUNDS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2003-03-06 | — | — | WO | claimed |
| CN-1356988-A | Phenoxy fluoropyrimidines | BAYER AG (DE) | 2002-07-03 | — | — | CN | claimed |
| EP-1194417-A1 | PHENOXY FLUOROPYRIMIDINES | BAYER AG (DE) | 2002-04-10 | — | — | EP | claimed |
| WO-2000078733-A1 | PHENOXY FLUOROPYRIMIDINES | BAYER AKTIENGESELLSCHAFT (DE) | 2000-12-28 | — | — | WO | claimed |
| EP-3242875-B1 | 4,5-DIHYDROIMIDAZOLE DERIVATIVES AND THEIR USE AS HISTONE DEMETHYLASE (KDM2B) INHIBITORS | GENENTECH INC (US) | 2022-02-23 | — | — | EP | disclosed |
| CN-107406418-B | 4, 5-dihydroimidazole derivatives and their use as histone demethylase (KDM2B) inhibitors | 基因泰克公司 | 2021-10-29 | — | — | CN | disclosed |
| CN-110320755-A | Minus white photosensitive resin composition and its application | 奇美实业股份有限公司 | 2019-10-11 | — | — | CN | disclosed |
| US-10221139-B2 | Inhibitors of histone demethylases | GILEAD SCIENCES, INC. (US) | 2019-03-05 | — | — | US | disclosed |
| EP-0192111-B1 | ISO-UREAS, PROCESSES FOR THEIR PRODUCTION AND THEIR USE AS HERBICIDES | BASF Aktiengesellschaft (DE) | 1990-05-16 | — | — | EP | disclosed |
| US-4766213-A | 1,4-dihydropyridines | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1988-08-23 | — | — | US | disclosed |
| EP-0237695-A2 | 1,4-Dihydropyridines | MERCK PATENT GmbH (DE) | 1987-09-23 | — | — | EP | disclosed |
| US-4692187-A | HERBICIDES | BASF AKTIENGESELLSCHAFT (DE) | 1987-09-08 | — | — | US | disclosed |
| EP-0192111-A1 | Iso-ureas, processes for their production and their use as herbicides | BASF Aktiengesellschaft (DE) | 1986-08-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180022707-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | KDM1B, KDM6B, KDM2B | RAB9A 2849/4885NPC1 1175/4885HPGD 1780/4885 |
| US-10221139-B2 | Inhibitors of histone demethylases | EHMT1, KDM1B, EHMT2 | RAB9A 2587/4885NPC1 2738/4885HPGD 599/4885 |
| US-10202354-B2 | Therapeutic compounds and uses thereof | KDM1B, KDM6B, KDM2B | RAB9A 2849/4885NPC1 1175/4885HPGD 1780/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.